# Aclaris Therapeutics, Inc. (ACRS)

> Source: Nexqual · https://nexqual.com/ACRS · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Aclaris Therapeutics, Inc. (ACRS), nexqual.com/ACRS" · informational, not investment advice.

**Price:** USD 3.99 (+0.76% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 3.96 · day 3.96–4.08 · 52w 2.1–6.6 · market cap $587M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $8.2M, net income -$75.7M (-921.5% margin), free cash flow -$62.2M (SEC filings).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (12 analysts), mean target USD 10.09 (range 4–16).
- Total return with dividends: 1Y +59.0% vs S&P 500 +14.8%; 5Y -77.0% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05 (date not yet confirmed by the company), EPS estimate USD -0.16, revenue estimate $1.2M. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
- Dividend: ACRS paid no cash dividend in the last five years.
- Short interest: 11.59% of float (as of 2026-10-15), 3.9 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $6.8M | $29.8M | $31.2M | $18.7M | $7.8M | $8.2M |
| Gross profit | $2.0M | $25.7M | $27.8M | $15.9M | $5.7M | — |
| Operating income | -$89.7M | -$89.9M | -$97.4M | -$142M | -$76.4M | -$86.3M |
| Net income | -$90.9M | -$86.9M | -$88.5M | -$132M | -$64.9M | -$75.7M |
| EPS (diluted) | -$1.60 | -$1.33 | -$1.27 | -$1.71 | -$0.53 | — |
| Free cash flow | -$52.4M | -$68.2M | -$79.6M | -$20.2M | -$47.2M | -$62.2M |
| Gross margin | 30.3% | 86.5% | 89.0% | 85.1% | 73.3% | — |
| Operating margin | -1327.1% | -302.0% | -311.6% | -758.2% | -975.9% | -1050.2% |
| Net margin | -1344.0% | -292.1% | -283.1% | -705.5% | -829.6% | -921.5% |
| Revenue growth | +4.3% | +340.1% | +5.0% | -40.1% | -58.2% | — |
| Cash + short-term investments | $226M | $230M | $182M | $204M | $151M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 71.5x · P/B 4.7x · FCF yield -10.59% · Earnings yield -12.90%

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 12 analysts; mean target USD 10.09 (low 4, high 16).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-28 | Wedbush | Target lowered | Outperform | $10 → $8 |
| 2026-10-28 | HC Wainwright & Co. | Reiterated | Buy | $16 |
| 2026-09-01 | Canaccord Genuity | Initiated | Buy | $10 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +59.0% | -77.0% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +59.5% | -25.4% |
| Volatility (annualized) | 88.3% | 106.3% |
| Max drawdown | -49.8% (Aug 2026→Oct 2026) | -95.4% (Nov 2022→Nov 2023) |

## Dividends
ACRS paid no cash dividend in the last five years.

## Short interest
15,027,284 shares sold short, 11.59% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 16,075,295 shares (-6.5%). Days to cover: 3.9 (short shares ÷ average daily volume).

## Peers (Biotechnology)
KOD (Kodiak Sciences Inc) USD 100.4 +3.46% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 93.07 +1.20% · ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/ACRS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.16 | $-0.17 | +$0.01 | $1.2M | 11 |
| Next quarter (ends 2026-12-31) | $-0.18 | $-0.17 | −$0.01 | $1.3M | 11 |
| Current fiscal year (ends 2026-12-31) | $-0.64 | $-0.66 | +$0.01 | $6.2M | 11 |
| Next fiscal year (ends 2027-12-31) | $-0.74 | $-0.83 | +$0.09 | $5.3M | 11 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.15 | −$0.16 | Beat +6.3% | — |
| — | Quarter ended Mar 31, 2026 | −$0.15 | −$0.16 | Beat +6.3% | — |
| — | Quarter ended Dec 31, 2025 | −$0.16 | −$0.14 | Miss −14.3% | — |
| — | Quarter ended Sep 30, 2025 | −$0.12 | −$0.14 | Beat +14.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).